Header cover image

Undervalued Growth Stock with 6% Yield and Expansion Potential

DR
DrBioHackerNot Invested
Community Contributor

Published

January 26 2025

Updated

February 04 2025

1. Business Overview and Market Scope

  • What the Business Does: Acrow is a Sydney-based provider of support services for the construction industry. Its primary offerings include formwork (temporary or permanent casings for pouring fresh concrete), scaffolding supplies, and services. Recent acquisitions, such as MI Scaffold and Benchmark Scaffolding & Edge Protection, have enhanced its capabilities.
  • Problem Being Solved: Acrow addresses the need for efficient, safe, and reliable solutions in construction, particularly in scaffolding and formwork, which are critical for large-scale infrastructure, mining, and marine projects.
  • Geographic Reach: Acrow operates predominantly in Australia, with revenues generated across Queensland, New South Wales, and Victoria. Its focus remains on strengthening its position within the Australian market.

2. Financial Health and Valuation

  • Key Financial Indicators:
    • Revenue (FY2023): $168.5M; projected $215.3M in FY2024.
    • EBIT (FY2023): $37.7M; projected $53.7M in FY2024.
    • EBIT Margin (FY2023): 22.4%; projected increase to 24.9%.
    • Dividend Yield: 6.0% (an attractive yield for income-focused investors).
    • Price/Earnings Ratio: 8.5x (suggests a reasonable valuation compared to industry norms).
    • 5-Year Share Price Return: 32.9% p.a. (indicating strong historical performance).
  • Valuation: With a P/E ratio of 8.5 and a Price-to-NTA ratio of 3.9, the stock appears undervalued relative to its strong earnings growth and profitability. Its robust dividend yield further supports its attractiveness as an income-generating asset.

3. Market Position and Growth Potential

  • Industry and Competitive Position: Acrow is well-positioned within the Australian construction industry, particularly in the formwork and scaffolding segments. Its expertise in industrial services (supporting oil, gas, and mining) provides a competitive edge.
  • Growth Drivers:
    • Focus on infrastructure developments in Australia.
    • Expansion of cross-selling opportunities across its product lines (formwork, scaffolding, and jacking systems).
    • Recent acquisitions complement its core business and open new opportunities, particularly in mining and marine sectors.
    • New innovations like the Jumpform system and exposure to heavy-duty screen systems for major construction projects.
  • ESG Considerations: The report does not detail ESG factors, but its focus on infrastructure development aligns with long-term sustainability trends.

4. Risk and Performance Metrics

  • Volatility and Risk: The company operates in the construction sector, which is cyclical and sensitive to economic downturns. A slowdown in large construction projects (e.g., the commercial scaffolding division's recent 15% decline in demand) poses a potential risk.
  • Technical Trends: The stock has a 12-month high of $1.34 and a low of $0.81, currently trading at $0.98. Its price is closer to the lower range, suggesting potential for upside if the growth story materializes.
  • Broader Risks: Heavy reliance on infrastructure spending in Australia could be a risk if government funding or private investment slows.

5. Final Verdict

  • Investability Score: 4/5 Acrow demonstrates strong financial performance, attractive valuation, and growth potential driven by its expansion efforts and acquisitions. However, cyclical risks in the construction industry must be considered.
  • Buying Strategy: Consider buying on dips, particularly if market volatility creates opportunities closer to its 12-month low ($0.81). With a 6% dividend yield, it also appeals to income investors. Investors may also consider timing entry before anticipated earnings growth or infrastructure project announcements.

How well do narratives help inform your perspective?

Disclaimer

The user DrBioHacker holds no position in ASX:ACF. Simply Wall St has no position in any of the companies mentioned. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value
AU$1.2
5.6% undervalued intrinsic discount
DrBioHacker's Fair Value
Future estimation in
PastFuture-9m308m20142017202020232025202620292030Revenue AU$308.3mEarnings AU$40.5m
% p.a.
Decrease
Increase
Current revenue growth rate
13.58%
Trade Distributors revenue growth rate
0.15%